Quick Answer
Vor Biopharma Inc. reported Earnings Per Share Diluted of $70.50 (loss) per share for the year ending 2025.
- Vor Biopharma Inc. showed a decrease of -107.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Vor Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.50 (loss) per share | Q3 2021: $0.50 (loss) per share | Q1 2022: $0.61 (loss) per share | Q2 2022: $0.58 (loss) per share | Q3 2022: $0.63 (loss) per share | Q1 2023: $0.43 (loss) per share | Q2 2023: $0.45 (loss) per share | Q3 2023: $0.49 (loss) per share | Q1 2024: $0.45 (loss) per share | Q2 2024: $0.41 (loss) per share | Q3 2024: $8.05 (loss) per share | Q1 2025: $0.26 (loss) per share | Q2 2025: $12.56 (loss) per share | Q3 2025: $121.63 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Vor Biopharma Inc.'s Earnings Per Share Diluted has declined by 3,257.1%.
- Historical annual values: Fiscal year 2025: $70.50 (loss) per share | Fiscal year 2024: $34.03 (loss) per share | Fiscal year 2023: $1.75 (loss) per share | Fiscal year 2022: $2.33 (loss) per share | Fiscal year 2021: $2.10 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: